Balyasny Asset Management LLC Sage Therapeutics, Inc. Call Options Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $370,600 - $471,100	-10,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $402,600 - $573,700	10,000 New	10,000 $443,000
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $8.76 Million - $13.4 Million	-150,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $6.17 Million - $9.37 Million	150,000 New	150,000 $9.17 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $14.3 Million - $26.3 Million	-160,500 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $6.6 Million - $11.2 Million	80,500 Added 100.63%	160,500 $15.4 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $52.5 Million - $66.4 Million	-345,000 Reduced 81.18%	80,000 $12.9 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $14.9 Million - $41 Million	245,000 Added 136.11%	425,000 $70 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $11.1 Million - $15.9 Million	180,000	180,000 $11.2 Million

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.